All News

Current and future treatment in Sjogrens Syndrome @rheumnow #EULAR2024 Many failed trails - likely secondary to non validated outcomes. 3 major domains - sicca, extraglandular manifestations, constitutional https://t.co/cCYX1YCqG2

"T and B cells playing tennis" In Sjogren's Syndrome! Thomas Dorner - #EULAR2024 @rheumnow https://t.co/Lum0A9cY9U

https://twitter.com/bella_mehta/status/1801261835355566228/photo/1

Isolated ⬆️ serum #IgG4 level: 💎💎💎 (Dr. Stone): ❓How high? >5x ULN ➡️PPV 75%‼️ ❓Typical organ(s) involved? ❓Another explanation? #eular2024 #rheumx @eular_org @RheumNow https://t.co/pm6wjvi2Vt

Different clusters - subpopulations of Sjogrens syndrome may exist and getting patient input is important @RheumNow https://t.co/7v5MYzzotT

How to assess treatment in Sjogren's Syndrome #EULAR2024 @RheumNow 1) define the target population 2) standardize inclusion criteria 3) Restricting ESSDAI domain to 5 domains 4) Correct endpoint choice https://t.co/m7DvZdpuZa

#EULAR2024 POS0223 UK multicentre data showed real-world avacopan use in #vasculitis differed from RCT: it was started later;often combined w other IS; GC tapering varied; 20% had eGFR<15. Compared to historical cohort of GC taper, OR of clinical response in AVA was 3.6 @RheumNow https://t.co/MP3OrRSJ0U

https://twitter.com/Yuz6Yusof/status/1801257849542111609/photo/1

Sjogrens Syndrome - bench to bedside session. #EULAR2024 @RheumNow Important to concentrate on non infiltrative patients. (to find different / early phenotypes?) https://t.co/ezFkX6CW8l

Real world data of safety profiles in SpA and Secukinumab- in all age groups #POS0199 #EULAR2024 @RheumNow https://t.co/q0FFP2SMLl

https://twitter.com/bella_mehta/status/1801247623409549475/photo/1

Very contradictory study in Axial SpA- no evidence of better drug retention or better treatment response compared to a later start of treatment. Data of early and very early disease. POs0204 #EULAR2024 @RheumNow https://t.co/6ci6xfyRmq

https://twitter.com/bella_mehta/status/1801247072760353204/photo/1

What happens when RA patients only on csDMARDs want to stop their meds? in BIO-FLARE, only half flared within 6mo of stopping all csDMARDs suddenly. They’ve got a clinical predictive model. Many milder patients ask, and could benefit! #EULAR2024 POS0068 John Isaacs @RheumNow https://t.co/B7ZjP5Pj70

#EULAR2024 OP0206 In a cohort study, of pts with #lupus nephritis, 81% tapered IS ~32 mths post-renal response. Of this, 17% flared. Strategies for safe tapering: ensure CR is achieved, low SLEDAI-2K at 12mths, low SLEDAI-2K & on HCQ at the time of tapering initiation @RheumNow https://t.co/hAMAdsL7Jn

https://twitter.com/Yuz6Yusof/status/1801236983794078190/photo/1

Risk of developing RA increased in antibody double-positive and single-positive compared to seronegative individuals. Highest risk in double-positive in first year. Single-positive increased risk of RA for up to five years after testing. In double-positive the risk remained… https://t.co/XLDHK4d4AE https://t.co/3Ek8knGExU

Biosimilar uptake across the world. Interesting that rich countries use more biosimilars - presumably because they have bargaining power - and that means they can access even better pricing. #EULAR2024 POS0597 Leiden @RheumNow https://t.co/wZgA0JH5uu

https://twitter.com/drdavidliew/status/1801235368093822997/photo/1

Still a long way but fascinating re: computer vision of hand movement from @vincevenerito @ThomasHugle. Proof of concept training set shows decent correlation with DAS28-LDA & HAQ-DI. Much more work needed but the promise for telehealth is enticing #EULAR2024 POS0607 @RheumNow https://t.co/iXsdn9fvuH

https://twitter.com/drdavidliew/status/1801233282300097021/photo/1

Swedish/Danish cohort study in PsA 17000+ bionaïve 8000+ TNFi & 2000+ other MoA Overall non melanoma skin cancer rate 651 (505 BCC & 87 SCC) TNFi treated pts: HR 1.25 NMSC vs. bionaive (95CI 1.04 to 1.50) HR 1.19 NMSC vs. other MoA (ns) #EULAR2024 @RheumNow AbstOP0150 https://t.co/DVj8l7yFR6

https://twitter.com/AurelieRheumo/status/1801230838136213897/photo/1

“One way to get rid of TDM is to get more drugs, and that’s what we’re doing” - Gertjan Wolbink, the godfather of rheumatology therapeutic drug monitoring (TDM) #EULAR2024 @RheumNow https://t.co/SYM8hjMMPJ

https://twitter.com/drdavidliew/status/1801229073999638532/photo/1

TYK2i RCT 290 pts 12 wks in active PSA TAK-279 15mg 30 mg 53% 54% vs PBO 29% ACR 50 15mg 30 mg 26% 26% vs. PBO 10%response PASI 75 30 mg 46% vs. 15m 28% PBO 15% Safety profile acceptable Abstr#OP0138 #EULAR2024 @RheumNow https://t.co/thNuwvUgQp

https://twitter.com/AurelieRheumo/status/1801228048466870716/photo/1

Elegant talk of #interferon #gamma in #pyoderma #gangrenosum Vs #PG + #pyogenic #arthritis +#acne #autoinflammatory #syndromes #Papa syn IL18 differences between PG alone and together in syndrome #JAKi May be helpful #EULAR2024 @eular_org @RheumNow @ARD_BMJ @ACR_Journals https://t.co/plYldVdolS

In the ‘why therapeutic drug monitoring’ debate, we’ve heard a lot about TDM utility, but the con argument is interesting. Desiree van der Heijde compares TDM to IL-6 levels, which never displaced her DAS then puts up some confronting points. Interesting #EULAR2024 @RheumNow https://t.co/7zomungi3e

I have to say: upadacitinib looks very decent for GCA. Not a panacea, but it definitely does something & good safety during trial. Would love to eventually see: - H2H comparative effect vs toci, secukinumab - structural outcomes - long-term safety #EULAR2024 PBA0001 @RheumNow https://t.co/pHZgCKsoA9 https://t.co/5BxCkkLPti

Topics

All News

Do you get our email newsletter?